A microbioreactor is a way of “doing more with less” succinctly stated Wei-Xiang Sin, PhD, research scientist at SMART CAMP. As these tiny growth machines become even more sophisticated with machine ...

The healthcare pioneer shares insights on transformative diagnostics where precision medicine meets women’s health innovation ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

Request To Download Free Sample of This Strategic Report @ Highlighted with 36 tables and 60 figures, this 133-page report Asia Pacific Bioprocess Technology Market 2023-2033 by Product (Instruments, ...

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Merck shares tumbled after the drugmaker said it was halting shipments of a top-selling vaccine to China to ...

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted earnings per share for the year to range from $8.88 to ...

Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2024 Fortune Media IP Limited ...

Western Blotting MarketThe global western blotting market is on a steady growth trajectory, with market valuation expected to rise from USD 980.1 million in 2023 to USD 1,753.4 million by 2033, ...

The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...